Skip to content

An anti-TNF-α antibody mimetic to treat ocular inflammation

Research output: Contribution to journalArticle

Original languageEnglish
Article number36905
Number of pages10
JournalScientific Reports
Volume6
DOIs
DateAccepted/In press - 20 Oct 2016
DatePublished (current) - 22 Nov 2016

Abstract

Infliximab is an antibody that neutralizes TNF-α and is used principally by systemic administration to treat many inflammatory disorders. We prepared the antibody mimetic Fab-PEG-Fab (FpFinfliximab) for direct intravitreal injection to assess whether such formulations have biological activity and potential utility for ocular use. FpFinfliximab was designed to address side effects caused by antibody degradation and the presence of the Fc region. Surface plasmon resonance analysis indicated that infliximab and FpFinfliximab maintained binding affinity for both human and murine recombinant TNF-α. No Fc mediated RPE cellular uptake was observed for FpFinfliximab. Both Infliximab and FpFinfliximab suppressed ocular inflammation by reducing the number of CD45+ infiltrate cells in the EAU mice after a single intravitreal injection at the onset of peak disease. These results offer an opportunity to develop and formulate for ocular use, FpF molecules designed for single and potentially multiple targets using bi-specific FpFs.

Download statistics

No data available

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Nature at http://www.nature.com/articles/srep36905. Please refer to any applicable terms of use of the publisher.

    Final published version, 994 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups